Indian Journal of Endocrine Surgery and Research

Register      Login

VOLUME 17 , ISSUE 2 ( July-December, 2022 ) > List of Articles


Diagnostic Obscurity in a Case of Large Right Suprarenal Mass

Keywords : Chromophobe variant of renal cell carcinoma, MIBG scan, Pheochromocytoma

Citation Information : Diagnostic Obscurity in a Case of Large Right Suprarenal Mass. 2022; 17 (2):64-66.

DOI: 10.5005/jp-journals-10088-11194

License: CC BY-NC 4.0

Published Online: 30-12-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Aim: Aim of this case report is to highlight the difficulties we faced in differentiating renal mass from the adrenal mass. Background: MIBG positive uptake usually signify a neuroendocrine tumor. However, there is reported false positive MIBG uptake in the chromophobe variant of renal cell carcinoma (RCC). Case description: A postmenopausal lady in her early 70s presented to our outpatient clinic with right-sided flank pain radiating to the back. On examination, a right hypochondriac region lump of size 10 × 8 cm was found. Contrast-enhanced computed tomography (CECT) scan done elsewhere showed a large, well-defined, smooth, lobulated, heterogeneously enhancing soft tissue lesion involving the upper pole of the right kidney measuring 15.5 × 11.4 × 11.2 cm, suspected to be an adrenal mass. The hormonal evaluation was inconclusive and the iodine-123-meta-iodobenzylguanidine (MIBG) scan showed concentration in the right suprarenal region. In view of the inconclusiveness of the findings, a repeat dedicated adrenal protocol CECT scan was done, which showed a mass arising from the superior pole of the kidney. The patient underwent open radical nephrectomy and final histopathology showed a chromophobe variant of RCC, which had shown a false positive uptake in the MIBG scan. Conclusion: We must interpret radiological, clinical and pathological aspects of large suprarenal mass during evaluation and be aware of false positive uptakes in MIBG scan. Clinical significance: An MIBG scan is a good tool for assessing the functionality of the neuroendocrine lesion, but we should always keep in mind the other conditions that can take up MIBG.

  1. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016;175(2):G1–G34. DOI: 10.1530/EJE-16-0467. PMID: 27390021.
  2. Hannah-Shmouni F, Pacak K, Stratakis CA. Metanephrines for evaluating palpitations and flushing. JAMA 201725;318(4):385–386. DOI: 10.1001/jama.2017.5926. PMID: 28742886; PMCID: PMC7457564.
  3. Garg MK, Kharb S, Brar KS, et al. Medical management of pheochromocytoma: Role of the endocrinologist. Indian J Endocrinol Metab 2011;15(4):S329–S336. DOI: 10.4103/2230-8210.86976.
  4. Jacques WM, Lenders, Quan-Yang Duh, et al. Pheochromocytoma and paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014;99(6):1915–1942.
  5. Beierwaltes WH. Update on basic research and clinical experience with metaiodobenzylguanidine. Med Pediatr Oncol 1987;15(4): 163–169. DOI: 10.1002/mpo.2950150405. PMID: 3309601.
  6. Bhatia KS, Ismail MM, Sahdev A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 2008;69(2):181–188. DOI: 10.1111/j.1365-2265.2008.03256.x. Epub 2008 Apr 3. PMID: 18394016.
  7. Wiseman GA, Pacak K, O'Dorisio MS, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med 2009;50(9): 1448–1454. DOI: 10.2967/jnumed.108.058701.
  8. Fiebrich HB, Brouwers AH, Kerstens MN, et al. [F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 2009;94(10):3922–3930. DOI: 10.1210/jc.2009-1054.
  9. Milardovic R, Corssmit EP, Stokkel M. Value of 123I-MIBG scintigraphy in paraganglioma. Neuroendocrinology 2010;91(1):94–100. DOI: 10.1159/000242499. Epub 2009 Sep 25. PMID: 19786729.
  10. Takasu N, Hayashi M, Takara M, et al. False-positive 123I-metaiodobenzylguanidine (MIBG) scan in a patient with angiomyolipoma; positive MIBG scan does not necessarily indicate the presence of pheochromocytoma. Intern Med 2007;46(20):1717–1721. DOI: 10.2169/internalmedicine.46.0232. Epub 2007 Oct 15. PMID: 17938527.
  11. Inoue Y, Akahane M, Kitazawa T, et al. False positive uptake of metaiodobenzylguanidine in hepatocellular carcinoma. Br J Radiol 2002;75(894):548–551. DOI: 10.1259/bjr.75.894.750548.
  12. Granata C, Carlini C, Conte M, et al. False positive MIBG scan due to accessory spleen. Med Pediatr Oncol 2001;37(2):138–139. DOI: 10.1002/mpo.1183. PMID: 11496353.
  13. Rainis T, Ben-Haim S, Dickstein G. False positive metaiodobenzylguanidine scan in a patient with a huge adrenocortical carcinoma. J Clin Endocrinol Metab 2000;85(1):5–7. DOI: 10.1210/jcem.85.1.6252.
  14. Boland GW, Blake MA, Hahn PF, et al. Incidental adrenal lesions: Principles, techniques, and algorithms for imaging characterization. Radiology 2008;249(3):756–775. DOI: 10.1148/radiol.2493070976. PMID: 19011181.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.